98%
921
2 minutes
20
Background: Affective disorders represent a major global health burden. Animal models are widely used for modeling brain disorders and neuroactive drug discovery. A novel powerful tool in translational neuroscience research, zebrafish provide multiple behavioral assays relevant to anxiety-like and depression-related conditions (including despair-like behavior, a common feature in depression).
New Method: Here we introduce a novel behavioral paradigm for assessing zebrafish locomotion and despair-like phenotypes, the small 5-ml glass vertical cylinder immobility test (VCIT). Conceptually similar to rodent and other zebrafish 'despair'-like models, the VCIT protocol is based on restricting their locomotion vertically for 5min in head-first position, to assess their locomotion and despair-like immobility.
Results: The test was sensitive to acute and chronic stressors that increased immobility duration (alarm pheromone, net chasing and chronic sleep deprivation and 12-week unpredictable stress), as well as to bidirectional modulation of zebrafish behavior by various acute and chronic neuroactive drugs. VCIT immobility was reduced by psychostimulants nicotine and arecoline, as well as a conventional antidepressant fluoxetine. In contrast, the immobility in this test was increased by a pro-depressant dopamine-depleting drug reserpine, and remained unaltered by an anxiolytic agent ethanol or anxiogenic drugs caffeine and GBR-12909.
Comparisons With Existing Method(s): VCIT provides an easy-to-perform, minimally invasive, non-traumatic, and procedurally simpler and faster model of assessing zebrafish stress-evoked despair-like phenotypes.
Conclusions: VCIT is sensitive to various stress-related manipulations and their bidirectional pharmacological modulation, hence emphasizing the growing relevance and potential of zebrafish in advancing neuropsychiatric research and identifying innovative treatments for neuropsychiatric disorders.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jneumeth.2025.110569 | DOI Listing |
Alpha Psychiatry
August 2025
Department of Pharmacology, School of Pharmaceutical Science, Ohu University, Koriyama, 963-8611 Fukushima, Japan.
Objective: Hypothalamic‒pituitary‒adrenal axis response is essential for coping with acute stressors, while maladaptive stress coping may increase the risk of major depressive disorder. We previously demonstrated that behavioral patterns induced by prior psychological stress predict coping levels in response to future stressors. This study investigated whether activating corticotropin-releasing hormone (CRH) and corticosteroid receptors mediates psychological stress-induced coping behavior.
View Article and Find Full Text PDFJ Neurosci Methods
September 2025
Department of Biosciences and Bioinformatics, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China; Suzhou Key Laboratory on Neurobiology and Cell Signaling, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China.
Background: Affective disorders represent a major global health burden. Animal models are widely used for modeling brain disorders and neuroactive drug discovery. A novel powerful tool in translational neuroscience research, zebrafish provide multiple behavioral assays relevant to anxiety-like and depression-related conditions (including despair-like behavior, a common feature in depression).
View Article and Find Full Text PDFMol Psychiatry
September 2025
Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Stress-related disorders, such as depression and anxiety, have been one of the most important medical issues. Accumulating evidence suggests that the activation of the pituitary adenylate cyclase-activating polypeptide and its receptor PAC1 are involved in the stress axis and the development of stress-related disorders. We recently developed PA-915, a small-molecule, non-peptide, high-affinity PAC1 antagonist, and demonstrated that it significantly suppresses anxiety-like behavior in acute stress-induced mice.
View Article and Find Full Text PDFBehav Pharmacol
October 2025
Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR.
Chronic unpredictable mild stress (CUMS) is an approved method for the induction of depression in rodents. Lithium, as one of the oldest psychiatric drugs, can induce beneficial effects on mood state under stressful conditions. On the other hand, crocin (active component of Saffron) has antioxidant, procognitive, and mood-enhancer effects.
View Article and Find Full Text PDFDrug Des Devel Ther
September 2025
Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Background: Depression is a complex neuropsychiatric disorder involving neuroinflammation, synaptic dysfunction, and neurotransmitter dysregulation. Recent studies have highlighted the therapeutic potential of short-acting anesthetics in the treatment of depression. Ciprofol, a novel intravenous anesthetic with rapid onset and recovery, shows promise, although its antidepressant mechanisms remain underexplored.
View Article and Find Full Text PDF